Luye Pharma Group Ltd.
Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 686
- Registration Number
- NCT06128837
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06098599
- Locations
- 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
A Pharmacokinetic Similarity Study in Healthy Male Subjects to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of LY06006 Versus US-Prolia and EU-Prolia by Single-dose Subcutaneous Injection
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT06095427
- Locations
- 🇩🇪
Parexel International GmbH, Early Phase Clinical Unit Berlin, Berlin, Germany
🇩🇪CTC North GmbH & Co KG, Hamburg, Germany
A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 555
- Registration Number
- NCT05970510
- Locations
- 🇨🇳
Peking University Sixth Hospital, Beijing, China
Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT05865925
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
A Dose-escalation Study of LPM3480392 in Chinese Healthy Subjects
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT05862974
- Locations
- 🇨🇳
The second affiliated hosipital zhejiang university school of medicine, Hangzhou, Zhejiang, China
Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg
- Conditions
- Interventions
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05856630
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China
An Exploratory Study of LPM3480392 at Different Infusion Rates in Chinese Healthy Subjects
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 23
- Registration Number
- NCT05857449
- Locations
- 🇨🇳
The second affiliated hosipital zhejiang university school of medicine, Hangzhou, Zhejiang, China
Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05853341
- Locations
- 🇩🇪
SocraTec R&D GmbH, Clinical Pharmacology Unit, Erfurt, Thüringen, Germany
Comparative Efficacy, Safety, PK, and Immunogenicity Study
- Conditions
- Interventions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 392
- Registration Number
- NCT05853354
- Locations
- 🇯🇵
Gifu Prefectural General Med C., Gifu, Gihu, Japan
🇯🇵Marunouchi Hospital, Matsumoto-shi, Nagano, Japan
🇯🇵Obase Hospital - Orthopedics, Miyako-gun, Hukuoka, Japan